Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.
Francesca FontanaAlison K EsserChristopher EgbulefuPartha KarmakarXinming SuJohn S AllenYalin XuJennifer L DavisAriel GabayJingyu XiangKristin A KwakwaBrad ManionSuzanne BakewellShunqiang LiHaeseong ParkGregory M LanzaSamuel AchilefuKatherine N WeilbaecherPublished in: PloS one (2023)
TfR is expressed in breast cancer, primary, metastatic, and after neoadjuvant chemotherapy. Variability in expression of TfR suggests that evaluation of the expression of TfR in individual patients could identify the best candidates for targeting. Further, systemic iron chelation with DFO may upregulate receptor expression and improve uptake of therapeutics or tracers that use transferrin as a homing ligand.
Keyphrases
- neoadjuvant chemotherapy
- poor prognosis
- metastatic breast cancer
- end stage renal disease
- binding protein
- squamous cell carcinoma
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- long non coding rna
- lymph node
- cancer therapy
- sentinel lymph node
- early stage
- prognostic factors
- radiation therapy
- single molecule
- rectal cancer
- breast cancer risk